¼¼°èÀÇ À§¾Ï Ä¡·á ½ÃÀå
Stomach Cancer Treatment
»óǰÄÚµå : 1777586
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 371 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À§¾Ï Ä¡·á ½ÃÀåÀº 2030³â±îÁö 104¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 52¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À§¾Ï Ä¡·á ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 12.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 104¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠǥÁØÈ­Çпä¹ýÀº CAGR 13.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 70¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç¥ÀûÄ¡·á ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 14¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 16.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À§¾Ï Ä¡·á ½ÃÀåÀº 2024³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 22¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 16.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 8.7%¿Í 10.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À§¾Ï Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À§¾Ï Ä¡·á°¡ Àü ¼¼°è¿¡¼­ ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡¼­ ´Ù½Ã ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

À§¾ÏÀº ¿©ÀüÈ÷ Àü ¼¼°è ¾Ï °ü·Ã »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, ƯÈ÷ µ¿¾Æ½Ã¾Æ, µ¿À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ÀϺΠÁö¿ª¿¡¼­´Â ¿©ÀüÈ÷ ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù. ½Äǰ ¾ÈÀü¼º Çâ»ó, Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ Á¦±Õ, Á¶±â °ËÁø µîÀÇ ³ë·ÂÀ¸·Î ÀϺΠÁö¿ª¿¡¼­´Â Àüü ¹ßº´·üÀÌ °¨¼ÒÇϰí ÀÖÁö¸¸, ¸¹Àº ±¹°¡¿¡¼­´Â Áø´ÜÀÌ ´Ê°í Ä¡·á Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖÀ¸¸ç, ¿©ÀüÈ÷ Å« °Ç°­ ¹®Á¦·Î ³²¾Æ ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á°è´Â À§¾Ï¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó, °ËÁø ±¸»ó È®´ë, µ¥ÀÌÅÍ ¼öÁý °³¼± µîÀ» ÅëÇØ À§¾ÏÀÇ ÁøÁ¤ÇÑ ºÎ´ãÀ» °­Á¶ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀϺ», Çѱ¹, Áß±¹ µî À§Çèµµ°¡ ³ôÀº ±¹°¡¿¡¼­´Â ü°èÀûÀÎ °ËÁø ÇÁ·Î±×·¥À» ÅëÇØ Ä¡·á °¡´ÉÇÑ Ãʱ⠴ܰ迡¼­ ´õ ¸¹Àº »ç·Ê¸¦ ¹ß°ßÇÏ¿© ±Ùº»ÀûÀÎ ¿Ü°úÀû Ä¡·á¿Í ¾à¸®ÇÐÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. À§¾ÏÀÌ ´õ ÁøÇàµÈ ´Ü°è¿¡¼­ ¹ßº´ÇÏ´Â °æÇâÀÌ ÀÖ´Â À¯·´°ú ¹Ì±¹¿¡¼­´Â »ýÁ¸±â°£À» ¿¬ÀåÇÏ°í »îÀÇ ÁúÀ» °³¼±ÇÏ´Â »õ·Î¿î Àü½Å¿ä¹ý¿¡ ´ëÇÑ ÀÓ»óÀû °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ÃÊÁ¡Àº Àü ¼¼°è¿¡¼­ À§¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» °ü¸®ÇÏ°í ±Ã±ØÀûÀ¸·Î °¨¼Ò½Ã۱â À§ÇØ Á¦¾à ±â¼ú Çõ½Å, ÀÇ·á ½Ã½ºÅÛ °èȹ ¹× Çмú¿¬±¸¸¦ º¸´Ù Çù·ÂÀûÀ̰í Àü·«ÀûÀÎ ³ë·ÂÀ¸·Î ¹ßÀü½ÃÄÑ ³ª°¡°í ÀÖ½À´Ï´Ù.

Ç¥ÀûÄ¡·á¿Í ¸é¿ªÁ¾¾çÇÐÀº ¾î¶»°Ô Ä¡·áÀÇ Àü¸ÁÀ» ÀçÁ¤ÀÇÇϰí Àִ°¡?

À§¾Ï Ä¡·á »óȲÀº Á¤¹ÐÀÇ·á, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, ¸é¿ªÄ¡·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î Å« º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸¿¡´Â ¼ö¼ú, È­Çпä¹ý, ¹æ»ç¼± Ä¡·á·Î Ä¡·áÇÏ´ø À§¾ÏÀº ÇöÀç ºÐÀÚ ¾ÆÇü, À¯ÀüÀÚ º¯ÀÌ, PD-L1 ¹ßÇö ¼öÁØ µîÀ» °í·ÁÇÑ ¸ÂÃãÇü Á¢±Ù¹ýÀ¸·Î °ü¸®µÇ°í ÀÖ½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿°ú °°Àº HER2 Ç¥ÀûÄ¡·áÁ¦´Â HER2 ¾ç¼º À§¾Ï ȯÀÚÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±½ÃÄ×°í, »õ·Î¿î Ç×ü¾à¹°Á¢ÇÕü(ADC)¿Í Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦´Â ´Ù¸¥ ¾Ï À¯¹ß ÀÎÀÚ¿¡ ´ëÇÑ Ä¡·á¹ýÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. Æèºê·Ñ¸®ÁÖ¸¿À̳ª ´Ïº¼·ç¸¿°ú °°Àº ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â ÁøÇ༺ ¶Ç´Â ÀüÀ̼º À§¾Ï ȯÀÚ, ƯÈ÷ ¹Ì¼¼ À§¼º ºÒ¾ÈÁ¤¼º(MSI-H)ÀÌ ³ô°Å³ª Á¾¾ç µ¹¿¬º¯ÀÌ ºÎÇÏ(TMB)°¡ ³ôÀº ȯÀÚ¿¡¼­ À¯¸Á °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ý°ú È­Çпä¹ý ¹× Ç×Ç÷°ü½Å»ýÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀº ³»¼ºÀ» ±Øº¹ÇÏ°í ¹ÝÀÀ Áö¼Ó¼ºÀ» °³¼±Çϱâ À§ÇØ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¾×ü»ý°Ë°ú Â÷¼¼´ë ½ÃÄö½ÌÀº ´õ ºü¸£°í Á¤È®ÇÑ Ä¡·á¹ý ¼±ÅÃÀ» ¿ëÀÌÇÏ°Ô ÇÏ¿© À§¾Ï ȯÀÚÀÇ °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ ½Ã´ë¸¦ ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ °¡¼ÓÈ­µÇ°í ÀÓ»ó½ÃÇè ÆÄÀÌÇÁ¶óÀÎÀÌ °­È­µÊ¿¡ µû¶ó ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ¹ßÀüÀº 1Â÷ Ä¡·á¿Í ³­Ä¡¼º Ä¡·á ¸ðµÎ¿¡¼­ Ç¥ÁØ Ä¡·á¸¦ Å©°Ô ÀçÆíÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼ö¿ä´Â ¾îµð¿¡¼­ È®´ëµÇ°í ÀÖÀ¸¸ç, ¾î¶² ȯÀÚ Áý´ÜÀÌ Ä¡·á ¼ö¿ä¸¦ ÁÖµµÇϰí Àִ°¡?

À§¾Ï Ä¡·á¿¡ ´ëÇÑ ½ÃÀå ¼ö¿ä´Â Àü ¼¼°è¿¡¼­ Áõ°¡Çϰí ÀÖÁö¸¸, ȯÀÚ ºÎ´ãÀÌ °¡Àå Å« °÷Àº Áß±¹, ÀϺ», Çѱ¹ µî ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡·Î Àü ¼¼°è ȯÀÚ ¼öÀÇ Àý¹Ý ÀÌ»óÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À̵é Áö¿ªÀº Àû±ØÀûÀÎ °ËÁø Á¤Ã¥, °­·ÂÇÑ Á¤ºÎ Áö¿ø, È®¸³µÈ Ä¡·á ÇÁ·ÎÅäÄÝÀÌ Æ¯Â¡À̸ç, Á¶±â °³ÀÔ°ú ÀǾàǰ ÆÇ¸Å Ãø¸é¿¡¼­ ÇÖ½ºÆÌÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹, µ¶ÀÏ, ¿µ±¹ µî ¼­À¯·´ ±¹°¡¿¡¼­´Â À§¾ÏÀÇ ¹ßº´·üÀÌ »ó´ëÀûÀ¸·Î ³·Àº ¹Ý¸é, À§¾ÏÀÇ ÀþÀº ¿¬·ÉÃþÀ¸·ÎÀÇ À̵¿°ú ³ôÀº ÁøÇà±â ¹ßº´·ü·Î ÀÎÇØ Ä¡·á ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«, µ¿À¯·´, ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª¿¡¼­´Â À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÁö¸¸, ¹ß°ß Áö¿¬, Ä¡·á ÀÎÇÁ¶ó, ¾à¹° Á¢±Ù¼º µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, Á¦³×¸¯ È­Çпä¹ýÁ¦, ¹ÙÀÌ¿À½Ã¹Ð·¯, °øÁߺ¸°Ç ÆÄÆ®³Ê½ÊÀÇ ±âȸ°¡ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ½Å±Ô Áø´ÜÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °í·É ȯÀÚµéÀº Àúµ¶¼º, ³»¾à¼º ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖÀ¸¸ç, ÀþÀº ȯÀÚµéÀº °¡ÀÓ·Â º¸Á¸ Ä¡·á¿Í Àå±â »ýÁ¸ °èȹ¿¡ ´ëÇÑ °ü½ÉÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. µµ½ÃÈ­, ½Ä½À°üÀÇ º¯È­, °³¹ßµµ»ó±¹¿¡¼­ÀÇ Áö¼ÓÀûÀÎ Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ °¨¿°µµ Ä¡·á ´ë»ó Àα¸ÀÇ ²ÙÁØÇÑ Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Àû½Ã¿¡ È¿°úÀûÀ̰í Àú·ÅÇÑ Ä¡·á¸¦ Á¦°øÇÏ´Â ÀÇ·á ½Ã½ºÅÛ¿¡ ´ëÇÑ ¾Ð·ÂÀ» °¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°è À§¾Ï Ä¡·á ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå µ¿·ÂÀº?

À§¾Ï Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº Àα¸ µ¿Çâ, ÁøÈ­ÇÏ´Â Ä¡·á ¿É¼Ç, Á¤Ã¥Àû ÇÁ·¹ÀÓ¿öÅ©, Áø´ÜÀÇ ¹ßÀüÀÌ °áÇÕÇÏ¿© ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ ÁÖ¿ä ¿äÀÎÀº Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ­, À§¾ÏÀÇ ±âÁؼ± À§Çè Áõ°¡, Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ±ºÀÇ È®´ëÀÔ´Ï´Ù. ºÐÀÚ ÇÁ·ÎÆÄÀϸµ°ú µ¿¹Ý Áø´ÜÀÇ ¹ßÀüÀ¸·Î Á¾¾ç Àü¹®ÀǵéÀº "ȹÀÏÀûÀÎ" È­Çпä¹ý¿¡¼­ ƯÁ¤ Á¾¾ç »ý¹°ÇÐÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â Á¤¹Ð ±â¹Ý ¿ä¹ýÀ¸·Î ÀüȯÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, À̸¦ ÅëÇØ È¿´ÉÀ» ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¾Ï ¸é¿ªÄ¡·áÀÇ ¼¼°è°¡ È®´ëµÇ¸é¼­ ÁøÇ༺ ÁúȯÀ̳ª ³­Ä¡¼º Áúȯ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á±â°üÀº Á¶±â¹ß°ß°ú Ä¡·á Á¢±Ù¼ºÀ» ¿ì¼±½ÃÇÏ´Â ¾Ï ´ëÃ¥ ÇÁ·Î±×·¥¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, Á¦¾à»çµéÀº ƯÈ÷ º´¿ë¿ä¹ý ¹× Â÷¼¼´ë »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚ °­È­·Î ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ½ÅÈï ½ÃÀå¿¡¼­´Â Á¾¾çÇÐ ÀÎÇÁ¶ó ±¸Ãà°ú ÀǾàǰ »óȯ Á¤Ã¥ÀÇ °³ÇõÀÌ ÁøÇàµÇ¾î ±âÁ¸ Ä¡·á¹ý°ú »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿ø°Ý Á¾¾çÇÐ, ÀüÀÚÀǹ«±â·Ï, ±¹Á¦ °øµ¿ ÀÓ»ó½ÃÇèÀÇ ¿ªÇÒÀÌ Áõ°¡Çϸ鼭 ȯÀÚ °ü¸®¿Í µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ Ä¡·áÀÇ ÃÖÀûÈ­°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù. À§¾Ï¿¡ ´ëÇÑ °úÇÐÀû ÀÌÇØ°¡ ±í¾îÁö°í Ä¡·á¹ý Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó À§¾Ï Ä¡·á ½ÃÀåÀº ¼¼°è¿¡¼­ °¡Àå °ø°ÝÀûÀ̰í Áø´ÜÀÌ ¾î·Á¿î ¾Ç¼º Á¾¾ç Áß Çϳª¿¡ ´ëóÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ» ¹è°æÀ¸·Î Áö¼ÓÀûÀÎ ¼ºÀå ż¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(Ç¥ÁØÈ­Çпä¹ý, Ç¥ÀûÄ¡·á, ¸é¿ªÄ¡·á), ÀûÀÀ Áúȯ(À§¾Ï/À§½Äµµ Á¢ÇպΠ¾Ï, À§Àå°ü ±âÁú Á¾¾ç), Åõ¿© °æ·Î(°æ±¸Á¦, ÁÖ»çÁ¦)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Stomach Cancer Treatment Market to Reach US$10.4 Billion by 2030

The global market for Stomach Cancer Treatment estimated at US$5.2 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Standard Chemotherapy, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 16.6% CAGR

The Stomach Cancer Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Stomach Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Stomach Cancer Treatment Receiving Renewed Global Focus Across Healthcare Systems?

Stomach cancer, or gastric cancer, remains one of the leading causes of cancer-related mortality worldwide, particularly in East Asia, Eastern Europe, and parts of Latin America. While overall incidence is declining in some regions due to improved food safety, Helicobacter pylori eradication, and early screening efforts, it continues to pose a significant health challenge due to late-stage diagnosis and limited treatment accessibility in many countries. The global healthcare community is shifting its focus toward stomach cancer due to rising awareness, expanded screening initiatives, and improvements in data collection that underscore the disease's true burden. In high-risk countries such as Japan, South Korea, and China, organized screening programs are detecting more cases at an earlier, potentially curable stage-driving a surge in demand for curative surgical and pharmacologic interventions. In the West, where stomach cancer tends to present at more advanced stages, there is growing clinical attention on novel systemic therapies that can extend survival and improve quality of life. This renewed focus is pushing pharmaceutical innovation, health system planning, and academic research into more coordinated, strategic efforts to manage and eventually reduce stomach cancer mortality on a global scale.

How Are Targeted Therapies and Immuno-Oncology Redefining the Treatment Landscape?

The stomach cancer treatment landscape is undergoing a major transformation fueled by advances in precision medicine, biomarker testing, and immunotherapy. Traditionally treated with surgery, chemotherapy, and radiation, stomach cancer is now being managed with more tailored approaches that consider molecular subtypes, genetic mutations, and PD-L1 expression levels. HER2-targeted therapies, such as trastuzumab, have significantly improved outcomes for patients with HER2-positive gastric cancer, while new antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors are expanding the arsenal against other oncogenic drivers. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in patients with advanced or metastatic gastric cancer, particularly in those with high microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB). Combination therapies-pairing immunotherapy with chemotherapy or anti-angiogenic agents-are being explored to overcome resistance and improve response durability. Liquid biopsies and next-generation sequencing are facilitating earlier and more accurate treatment selection, ushering in an era of personalized care for stomach cancer patients. As regulatory approvals accelerate and clinical trial pipelines deepen, these therapeutic advances are expected to significantly reshape the standard of care in both first-line and refractory settings.

Where Is Market Demand Expanding, and Which Patient Populations Are Driving Treatment Needs?

Market demand for stomach cancer treatment is rising globally, with the highest patient burden concentrated in Asia-Pacific countries such as China, Japan, and South Korea, which account for over half of the world’s cases. These regions are characterized by proactive screening policies, strong government support, and well-established treatment protocols, making them hotspots for both early intervention and pharmaceutical sales. In Western countries, including the United States, Germany, and the UK, although incidence is comparatively lower, a shift toward younger-onset gastric cancer cases and high rates of advanced-stage presentation are intensifying treatment demands. Latin America, Eastern Europe, and parts of Africa are experiencing growing prevalence but face challenges related to late detection, treatment infrastructure, and drug access-highlighting opportunities for generic chemotherapy agents, biosimilars, and public health partnerships. Elderly patients, who account for a large proportion of new diagnoses, are driving demand for less toxic, more tolerable regimens, while younger patients are prompting interest in fertility-sparing treatments and long-term survivorship planning. Urbanization, dietary shifts, and persistent H. pylori infection in developing regions are also contributing to a steady expansion in the treatment-eligible population, creating pressure on healthcare systems to provide timely, effective, and affordable care.

What’s Driving the Long-term Growth of the Stomach Cancer Treatment Market Globally?

The growth in the stomach cancer treatment market is driven by a confluence of demographic trends, evolving therapeutic options, policy frameworks, and diagnostic advancements. A primary long-term driver is the aging global population, which is increasing the baseline risk for stomach cancer and expanding the pool of patients needing treatment. Advances in molecular profiling and companion diagnostics are enabling oncologists to move away from “one-size-fits-all” chemotherapy to precision-based regimens that target specific tumor biology-improving efficacy and minimizing side effects. The global expansion of cancer immunotherapy is opening new treatment windows for advanced or previously intractable cases. Governments and health organizations are investing in cancer control programs that prioritize early detection and access to care, while pharmaceutical companies are responding with intensified R&D investment, particularly in combination therapies and next-gen biologics. In parallel, emerging markets are building oncology infrastructure and reforming drug reimbursement policies, broadening access to both established and novel therapies. The increasing role of tele-oncology, electronic health records, and global clinical trial collaboration is also enhancing patient management and data-driven treatment optimization. As scientific understanding of gastric cancer deepens and therapeutic innovations continue to emerge, the stomach cancer treatment market is poised for sustained growth-anchored by its crucial role in addressing one of the world’s most aggressive and underdiagnosed malignancies.

SCOPE OF STUDY:

The report analyzes the Stomach Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Standard Chemotherapy, Targeted Therapy, Immunotherapy); Disease Indication (Gastric Cancer / Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumors); Administration Route (Oral, Injectable)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â